Lantern Pharma
LTRN · NASDAQ
$0.6564+$0.0151 (+2.35%)TodayMarket closed ·
Prev close $0.6413
Who owns LTRN
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 38.8% of LTRN’s shares.
- Satterfield (Thomas A Jr)7.6%
- Biological Mimetics, Inc6.6%
- Empery Asset Management, L.P.6.6%
- Prophase Labs Inc4.9%
- Next 6 largest institutions13.0%
- All other shareholders61.2%
| Holder | Shares | % of shares |
|---|---|---|
| Satterfield (Thomas A Jr) | 975.00K | 7.64% |
| Biological Mimetics, Inc | 844.13K | 6.62% |
| Empery Asset Management, L.P. | 842.67K | 6.60% |
| Prophase Labs Inc | 631.20K | 4.95% |
| CM Management, LLC | 500.00K | 3.92% |
| Vanguard Capital Management, LLC | 425.12K | 3.33% |
| Renaissance Technologies LLC | 291.04K | 2.28% |
| Bios Equity Partners, LP. | 249.40K | 1.95% |
| Geode Capital Management, L.L.C. | 102.82K | 0.81% |
| Keyser (Donald Jeffrey PH.D) | 94.30K | 0.74% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 338.38K | 2.65% |
| Vanguard Extended Market Index Fund | 81.90K | 0.64% |
| Fidelity Extended Market Index Fund | 45.01K | 0.35% |
| Horizon Kinetics Medical ETF | 23.95K | 0.19% |
| Fidelity Series Total Market Index Fund | 17.48K | 0.14% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $200.00K (2 trades) of LTRN on the open market, with no sales.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Schalop Lee Troy | Buy | 48.54K | — |
| Schalop Lee Troy | Buy | 48.54K | $100.00K |
| KEYSER D JEFFREY | Buy | 48.54K | — |
| KEYSER D JEFFREY | Buy | 48.54K | $100.00K |
Short interest
Settled Sep 30, 2026
- Shares short
- 485.75K
- Days to cover
- 1.31
- % of shares outstanding
- 3.81%
- Average daily volume
- 369.54K
- Change since last report
- −12.9%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.